BEAM Beam Therapeutics Inc
Price (delayed)
$24.4
Market cap
$2.01B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.63
Enterprise value
$1.88B
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a
Highlights
The EPS has surged by 64% year-on-year
The debt has contracted by 7% YoY
The net income has surged by 56% year-on-year but it has declined by 6% since the previous quarter
BEAM's quick ratio is up by 10% year-on-year but it is down by 2.7% since the previous quarter
BEAM's gross profit is down by 2.3% since the previous quarter
Beam Therapeutics's revenue has decreased by 2.3% from the previous quarter
Key stats
What are the main financial stats of BEAM
Market
Valuations
Earnings
Shares outstanding
82.42M
Market cap
$2.01B
Enterprise value
$1.88B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.35
Price to sales (P/S)
5.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.32
Revenue
$352.57M
EBIT
-$141.61M
EBITDA
-$120.05M
Free cash flow
-$153.4M
Per share
Balance sheet
Liquidity
EPS
-$1.63
Free cash flow per share
-$1.86
Book value per share
$10.38
Revenue per share
$4.28
TBVPS
$15.32
Total assets
$1.26B
Total liabilities
$407.17M
Debt
$165.24M
Equity
$854.09M
Working capital
$852.11M
Debt to equity
0.19
Current ratio
5.81
Quick ratio
5.72
Net debt/EBITDA
1.11
Margins
Efficiency
Dividend
EBITDA margin
-34.1%
Gross margin
100%
Net margin
-40.6%
Operating margin
-52.3%
Return on assets
-10.6%
Return on equity
-16.2%
Return on invested capital
-14%
Return on capital employed
-13.1%
Return on sales
-40.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BEAM stock price
How has the Beam Therapeutics stock price performed over time
Intraday
1.16%
1 week
0.91%
1 month
1.75%
1 year
-6.8%
YTD
-10.36%
QTD
4.14%
Financial performance
How have Beam Therapeutics's revenue and profit performed over time
Revenue
$352.57M
Gross profit
$352.57M
Operating income
-$184.44M
Net income
-$143.01M
Gross margin
100%
Net margin
-40.6%
The net margin has soared by 90% YoY but it has contracted by 9% from the previous quarter
Beam Therapeutics's operating margin has surged by 89% YoY but it has decreased by 4% QoQ
The net income has surged by 56% year-on-year but it has declined by 6% since the previous quarter
Beam Therapeutics's operating income has surged by 52% YoY
Growth
What is Beam Therapeutics's growth rate over time
Valuation
What is Beam Therapeutics stock price valuation
P/E
N/A
P/B
2.35
P/S
5.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.32
The EPS has surged by 64% year-on-year
The price to book (P/B) is 61% lower than the 5-year quarterly average of 6.0 and 7% lower than the last 4 quarters average of 2.5
BEAM's equity is down by 7% since the previous quarter but it is up by 5% year-on-year
BEAM's price to sales (P/S) is 100% lower than its 5-year quarterly average of 46292.8 and 46% lower than its last 4 quarters average of 10.5
Beam Therapeutics's revenue has decreased by 2.3% from the previous quarter
Efficiency
How efficient is Beam Therapeutics business performance
The return on sales has surged by 90% year-on-year but it has declined by 9% since the previous quarter
The ROE has soared by 63% YoY but it has decreased by 4.5% QoQ
The company's return on assets has surged by 56% YoY but it fell by 7% QoQ
BEAM's ROIC has soared by 54% YoY but it is down by 9% QoQ
Dividends
What is BEAM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BEAM.
Financial health
How did Beam Therapeutics financials performed over time
Beam Therapeutics's total liabilities has decreased by 25% YoY and by 9% QoQ
BEAM's current ratio is up by 11% YoY but it is down by 3% QoQ
The debt is 81% less than the equity
The company's debt to equity fell by 14% YoY but it rose by 6% QoQ
BEAM's equity is down by 7% since the previous quarter but it is up by 5% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.